PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications.
The last earnings update was 9 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
PhaseBio Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
PhaseBio Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
PhaseBio Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
PhaseBio Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
PhaseBio Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
PhaseBio Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
PhaseBio Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
PhaseBio Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
PhaseBio Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 5.4x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Jonathan P. Mow, MBA has been Chief Executive Officer of PhaseBio Pharmaceuticals, Inc. since March 2015 and serves as its President. Mr. Mow served as Chief Business Officer of PhaseBio Pharmaceuticals, Inc since December 4, 2012. He served as Vice President of Commercial and Business Development and Secretary of Corus Pharma Inc. since January 2001. From January 2001 to February 2003, Mr. Mow served as Senior Director of Business Development of PathoGenesis Corporation, which was acquired by Chiron Corporation in September 2000. From 1995 to January 1997, he served as Director, Worldwide Oncology Strategic Business Planning at Bristol-Myers Squibb Company, a pharmaceutical company. From 1992 to 1995, Mr. Mow served in several positions at American Cyanamid Company, Lederle International Division, a pharmaceutical company, most recently as International Product Manager. From 1990 to 1992, Mr. Mow served as Marketing Research Analyst and Sales Representative of Syntex Laboratories, Inc. Mr. Mow has extensive experience in pharmaceutical marketing and business development. As co-founder of Corus Pharma, he was an integral member of the management team that positioned its aerosol drug pipeline to be acquired for approximately $420 million by Gilead Sciences in 2006. He serves as a Director of PhaseBio Pharmaceuticals, Inc. He served as a Director of AerovectRx Corporartion since February 2, 2007. He served as a Director of Corus Pharma Inc. from January 1997 to December 2000. Mr. Mow received his B.S. degree from University of California Berkeley and his M.S. (M.B.A.) degree from Carnegie Mellon University.
Jonathan's compensation has increased whilst company is loss making.
Jonathan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the PhaseBio Pharmaceuticals management team is about average.
Chief Financial Officer
Chief Medical Officer
VP & Head of Legal
Vice President of Corporate Development & Commercial Strategy
Vice President of Human Resources
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the PhaseBio Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors
Chairman of the Board
Rich van den Broek
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.